Osaka, Japan and London, UK, February 1 - Takeda Pharmaceutical Company Limited (“Takeda”) and Takeda Pharmaceuticals Europe Limited (“TPEU”), its wholly owned subsidiary for oversight of pan-European sales and marketing, jointly announced today that Mepact® (mifamurtide)1, the first new treatment in 20 years to improve survival in patients with osteosarcoma (malignant bone cancer)2, is now commer
http://digg.com/u1M0lp
No comments:
Post a Comment